44.31 Swiss Francs per Share...Tender Offer Opens September 15
Largest Shareholder Commits 55.65% Stake
"Expanding CDMO Portfolio into Peptides"

Samsung BioLogics has launched a public tender offer to acquire PolyPeptide Group, a global peptide contract development and manufacturing organization (CDMO).


On August 31, Samsung BioLogics announced that it had posted the public tender offer prospectus on its website, targeting the entire issued share capital of PolyPeptide Group, excluding treasury shares, totaling 33,016,411 shares.


Aerial view of Samsung BioLogics Plant 4 in Songdo, Incheon. Samsung BioLogics

Aerial view of Samsung BioLogics Plant 4 in Songdo, Incheon. Samsung BioLogics

View original image

According to the prospectus, Samsung BioLogics will conduct the acquisition through its special purpose subsidiary, Samsung Peptide, established specifically for this purpose. The tender offer price is set at 44.31 Swiss francs per share. If all shares are tendered, the total purchase price would be 1.46 billion Swiss francs (approximately 2.7 trillion won).


The board of directors of PolyPeptide Group unanimously supported the tender offer, and IFBC, a Swiss state-approved valuation entity and global financial advisory firm, also concluded that the offer price is fair.


'Draupnir Holding', the largest shareholder of PolyPeptide Group, has made a firm commitment to tender its entire holding of 18,375,000 shares in the offer. Draupnir Holding's stake represents approximately 55.65% of the company.


The tender offer period will run from September 15 to October 12, local time. In accordance with Swiss takeover law, if the tendered shares exceed the critical threshold of 66.7% required to ensure stable management decision-making, and all necessary regulatory approvals are obtained, the transaction will be finalized.


After the completion of the transaction, Samsung Peptide plans to proceed with the delisting process of PolyPeptide Group. Additionally, if it secures over 90% of the shares—a threshold required to forcibly acquire minority shareholders' remaining shares (squeeze-out)—it will execute this process.


Samsung BioLogics signed the acquisition agreement with PolyPeptide Group last month and aims to complete the final acquisition by the end of November through this public tender offer. Through this acquisition, Samsung BioLogics will expand its business portfolio from its current focus on antibody therapeutics, mRNA, and antibody-drug conjugates (ADCs) to the fast-growing peptide sector, thereby diversifying its portfolio and securing new long-term growth drivers.



Samsung BioLogics plans to maximize business synergy by combining its accumulated expertise in large-scale production facility design and operation with PolyPeptide Group's peptide development and manufacturing technologies. The company also intends to review expanding production facilities in response to future growth in the peptide market, so as to address customer demand in a timely manner.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing